In a phase 2b trial, efruxifermin significantly improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis, with the 50 mg dose showing the greatest benefit.
The FDA has announced the approval of the semaglutide injection to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis following promising interim analysis data.
...
The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
Based on recent scientific knowledge, the American Diabetes Association (ADA) released a set of updates including recommendations for the detection and management of nonalcoholic fatty liver disease in...
Identifying treatment options for patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis was among the key topics at the American Association for the Study of Liver Diseases session...
Nonalcoholic steatohepatitis is a potentially progressive form of nonalcoholic fatty liver disease. Recent research, which was discussed at the 21st Annual Harvard Nutrition and Obesity Symposium on NAFLD,...
During her presentation at CROI 2019, Dr Giada Sebastiani highlighted the prevalence of nonalcoholic steatohepatitis among individuals with HIV and what can be done to prevent progression of disease and...
